home / stock / vigl / vigl quote
Last: | $3.52 |
---|---|
Change Percent: | -0.56% |
Open: | $3.56 |
Close: | $3.52 |
High: | $3.63 |
Low: | $3.44 |
Volume: | 49,236 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.52 | $3.56 | $3.52 | $3.63 | $3.44 | 49,236 | 05-17-2024 |
$3.54 | $3.49 | $3.54 | $3.59 | $3.42 | 32,182 | 05-16-2024 |
$3.485 | $3.66 | $3.485 | $3.696 | $3.28 | 52,785 | 05-15-2024 |
$3.66 | $3.67 | $3.66 | $3.78 | $3.59 | 55,173 | 05-14-2024 |
$3.65 | $3.24 | $3.65 | $3.71 | $3.05 | 649,640 | 05-13-2024 |
$3.18 | $3.34 | $3.18 | $3.41 | $3.04 | 79,302 | 05-10-2024 |
$3.285 | $3.68 | $3.285 | $3.77 | $3.1775 | 194,996 | 05-09-2024 |
$3.78 | $3.19 | $3.78 | $3.8512 | $3.19 | 531,856 | 05-08-2024 |
$3.19 | $2.91 | $3.19 | $3.2 | $2.83 | 52,143 | 05-07-2024 |
$2.89 | $3.07 | $2.89 | $3.12 | $2.755 | 74,868 | 05-06-2024 |
$3.03 | $2.72 | $3.03 | $3.05 | $2.67 | 71,507 | 05-03-2024 |
$2.74 | $2.65 | $2.74 | $2.785 | $2.555 | 49,156 | 05-02-2024 |
$2.65 | $2.64 | $2.65 | $2.7729 | $2.51 | 46,194 | 05-01-2024 |
$2.61 | $2.6 | $2.61 | $2.66 | $2.545 | 39,199 | 04-30-2024 |
$2.6 | $2.74 | $2.6 | $2.8179 | $2.56 | 68,569 | 04-29-2024 |
$2.71 | $2.62 | $2.71 | $2.74 | $2.5 | 46,561 | 04-26-2024 |
$2.58 | $2.76 | $2.58 | $2.81 | $2.53 | 66,727 | 04-25-2024 |
$2.77 | $2.65 | $2.77 | $2.86 | $2.645 | 62,935 | 04-24-2024 |
$2.65 | $2.84 | $2.65 | $2.93 | $2.615 | 67,147 | 04-23-2024 |
$2.84 | $2.8 | $2.84 | $2.86 | $2.64 | 40,601 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Vigil Neuroscience Inc. Company Name:
VIGL Stock Symbol:
NASDAQ Market:
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to h...
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside cha...
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer’s disease ongoing; Interim data analysis on track for mid-2024 – W...